Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels

Molecular Pharmacology

Volumn 82, Issue 3, 2012, Pages 500-509

  Sjögren, Benita ^a   Parra, Sergio ^a   Heath, Lauren J ^a   Atkins, Kevin B ^a   Xie, Zie Jian ^c   Neubig, Richard R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA GALACTOSIDASE; DIGOXIN; LACTACYSTIN; MESSENGER RNA; OUABAIN; RGS2 PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENZYME PHOSPHORYLATION; GENE SILENCING; HEART FAILURE; HUMAN; HUMAN TISSUE; HYPERTENSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BETA-GALACTOSIDASE; CARDIAC GLYCOSIDES; CELLS, CULTURED; DIGOXIN; HEART; HEK293 CELLS; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OUABAIN; PROTEOLYSIS; RATS; RGS PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; SODIUM-POTASSIUM-EXCHANGING ATPASE; SWINE; UP-REGULATION;

EID: 84865270168     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079293     Document Type: Article

References (60)

1. Abramowitz J, Dai C, Hirschi KK, Dmitrieva RI, Doris PA, Liu L, and Allen JC (2003) Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and a rat vascular smooth muscle cell line, A7r5. Circulation 108:3048-3053.
2. Ahmed A and Waagstein F (2009) Low-dose digoxin and reduction in mortality and morbidity in heart failure. Int J Cardiol 136:91-92.
3. Atkins KB, Irey B, Xiang N, and Brosius FC 3rd (2009) A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT. Am J Physiol Cell Physiol 296:C1151-C1161.
4. Bagrov AY, Shapiro JI, and Fedorova OV (2009) Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 61:9-38.
5. Blazer LL and Neubig RR (2009) Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology 34:126-141.
6. Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, and Neubig RR (2010) Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol 78:524-533.
7. Blazer LL, Zhang H, Casey EM, Husbands SM, and Neubig RR (2011) A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins. Biochemistry 50:3181-3192.
8. Blundell J, Hoang CV, Potts B, Gold SJ, and Powell CM (2008) Motor coordination deficits in mice lacking RGS9. Brain Res 1190:78-85.
9. Bodenstein J, Sunahara RK, and Neubig RR (2007) N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. Mol Pharmacol 71:1040-1050.
10. Brinks HL and Eckhart AD (2010) Regulation of GPCR signaling in hypertension. Biochim Biophys Acta 1802:1268-1275.
11. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, and Semplicini A (2004) Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. a role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 89:4153-4157.
12. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, and Tu Y (2006) Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25:3719-3734.
13. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T, Deshpande SN, B K T, Ferrell RE, Middleton FA, et al. (2002) Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11:1373-1380.
14. da Costa Goncalves ACh, Luft FC, and Gross V (2008) Fine tuning of blood pressure by the regulator of G protein signaling (RGS) 2. J Am Soc Hypertens 2:403-409.
15. Detweiler DK (1967) Comparative pharmacology of cardiac glycosides. Fed Proc 26:1119-1124.
16. Doggrell SA (2004) Is RGS-2 a new drug development target in cardiovascular disease? Expert Opin Ther Targets 8:355-358.
17. Doupnik CA, Xu T, and Shinaman JM (2001) Profile of RGS expression in single rat atrial myocytes. Biochim Biophys Acta 1522:97-107.
18. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, and Schreiber SL (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731.
19. Gheorghiade M and Braunwald E (2009) Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 302:2146-2147.
20. Gu S, Anton A, Salim S, Blumer KJ, Dessauer CW, and Heximer SP (2008) Alternative translation initiation of human regulators of G-protein signaling-2 yields a set of functionally distinct proteins. Mol Pharmacol 73:1-11.
21. Gurley SB, Griffiths RC, Mendelsohn ME, Karas RH, and Coffman TM (2010) Renal actions of RGS2 control blood pressure. J Am Soc Nephrol 21:1847-1851.
22. Hendriks-Balk MC, Peters SL, Michel MC, and Alewijnse AE (2008) Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. Eur J Pharmacol 585:278-291.
23. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveirados-Santos A, Penninger JM, Muslin AJ, Steinberg TH, et al. (2003) Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 111:445-452.
24. Heximer SP, Watson N, Linder ME, Blumer KJ, and Hepler JR (1997) RGS2/G0S8 is a selective inhibitor of Gqα function. Proc Natl Acad Sci USA 94:14389-14393.
25. +-ATPase knockout mice. Am J Physiol Regul Integr Comp Physiol 296:R1427-R1438.
26. Krumins AM, Barker SA, Huang C, Sunahara RK, Yu K, Wilkie TM, Gold SJ, and Mumby SM (2004) Differentially regulated expression of endogenous RGS4 and RGS7. J Biol Chem 279:2593-2599.
27. Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G, Salvi E, Carpini SD, Ferrandi M, Messaggio E, Staessen JA, et al. (2010) Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci Transl Med 2:59ra87.
28. Lee MJ, Tasaki T, Moroi K, An JY, Kimura S, Davydov IV, and Kwon YT (2005) RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. Proc Natl Acad Sci USA 102:15030-15035.
29. Lee PC, Sowa ME, Gygi SP, and Harper JW (2011) Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. Mol Cell 43:392-405.
30. Liang M, Cai T, Tian J, Qu W, and Xie ZJ (2006) Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. J Biol Chem 281:19709-19719.
31. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) method. Methods 25:402-408.
32. Nguyen CH, Ming H, Zhao P, Hugendubler L, Gros R, Kimball SR, and Chidiac P (2009) Translational control by RGS2. J Cell Biol 186:755-765.
33. Nicholls MG, Lewis LK, Yandle TG, Lord G, McKinnon W, and Hilton PJ (2009) Ouabain, a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease: fact or fantasy? J Hypertens 27:3-8.
34. Nunn C, Zou MX, Sobiesiak AJ, Roy AA, Kirshenbaum LA, and Chidiac P (2010) RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell Signal 22:1231-1239.
35. Quintas LE, Pierre SV, Liu L, Bai Y, Liu X, and Xie ZJ (2010) Alterations of Na+/K+-ATPase function in caveolin-1 knockout cardiac fibroblasts. J Mol Cell Cardiol 49:525-531.
36. Riddle EL, Schwartzman RA, Bond M, and Insel PA (2005) Multi-tasking RGS proteins in the heart: the next therapeutic target? Circ Res 96:401-411.
37. Rindler TN, Dostanic I, Lasko VM, Nieman ML, Neumann JC, Lorenz JN, and Lingrel JB (2011) Knockout of the Na,K-ATPase α2-isoform in the cardiovascular system does not alter basal blood pressure but prevents ACTH-induced hypertension. Am J Physiol Heart Circ Physiol 301:H1396-H1404.
38. Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, and Neubig RR (2007) Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol Pharmacol 71:169-175.
39. Ross EM and Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 69:795-827.
40. Salazar NC, Chen J, and Rockman HA (2007) Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta 1768:1006-1018.
41. Salim S, Sinnarajah S, Kehrl JH, and Dessauer CW (2003) Identification of RGS2 and type V adenylyl cyclase interaction sites. J Biol Chem 278:15842-15849.
42. Schoenfeld JR, Vasser M, Jhurani P, Ng P, Hunter JJ, Ross J Jr, Chien KR, and Lowe DG (1998) Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol 30:2269-2280.
43. Semplicini A, Strapazzon G, Papparella I, Sartori M, Realdi A, Macchini L, Calò LA, and Ceolotto G (2010) RGS2 expression and aldosterone:renin ratio modulate response to drug therapy in hypertensive patients. J Hypertens 28:1104-1108.
44. Shah NK, Choksi R, and Epstein BJ (2011) Less RAAS is more, or not. Expert Rev Cardiovasc Ther 9:1363-1365.
45. Sjögren B, Blazer LL, and Neubig RR (2010) Regulators of G protein signaling proteins as targets for drug discovery. Prog Mol Biol Transl Sci 91:81-119.
46. Sjögren B and Neubig RR (2010) Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. Mol Pharmacol 78:550-557.
47. Skou JC (1957) The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta 23:394-401.
48. Sun X, Kaltenbronn KM, Steinberg TH, and Blumer KJ (2005) RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling. Mol Pharmacol 67:631-639.
49. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, et al. (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119:408-420.
50. iα1: stabilization of the transition state for GTP hydrolysis. Cell 89:251-261.
51. Tuomi JM, Chidiac P, and Jones DL (2010) Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse. Am J Physiol Heart Circ Physiol 298:H554-H561.
52. Turner EM, Blazer LL, Neubig RR, and Husbands SM (2012) Small molecule inhibitors of regulator of G protein signalling (RGS) proteins. ACS Med Chem Lett 3:146-150.
53. Weiss DN, Podberesky DJ, Heidrich J, and Blaustein MP (1993) Nanomolar ouabain augments caffeine-evoked contractions in rat arteries. Am J Physiol 265:C1443-C1448.
54. +-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 3:157-168.
55. Yang J, Kamide K, Kokubo Y, Takiuchi S, Tanaka C, Banno M, Miwa Y, Yoshii M, Horio T, Okayama A, et al. (2005) Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. J Hypertens 23:1497-1505.
56. Yeh JY, Huang WJ, Kan SF, and Wang PS (2001) Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol 166:1937-1942.
57. Zhang P, Su J, King ME, Maldonado AE, Park C, and Mende U (2011) Regulator of G protein signaling 2 is a functionally important negative regulator of angiotensin II-induced cardiac fibroblast responses. Am J Physiol Heart Circ Physiol 301:H147-H156.
58. Zhang W, Anger T, Su J, Hao J, Xu X, Zhu M, Gach A, Cui L, Liao R, and Mende U (2006) Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem 281:5811-5820.
59. Zhong H and Neubig RR (2001) Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 297:837-845.
60. Zou MX, Roy AA, Zhao Q, Kirshenbaum LA, Karmazyn M, and Chidiac P (2006) RGS2 is upregulated by and attenuates the hypertrophic effect of α1-adrenergic activation in cultured ventricular myocytes. Cell Signal 18:1655-1663.